Bellevue Life Sciences Acquisition Corp.
BLAC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -44.7% | 49.2% | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 41.7% | 2.9% | 22.2% | – |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 0% | -460.5% | -383.3% | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -508.9% | -460.2% | -1,496.6% | – |
| EPS Diluted | -0.71 | -1.17 | -2.54 | -0.45 |
| % Growth | 39.3% | 53.9% | -464.4% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |